Supporting the First-Ever Redosable Eye-Drop Gene Therapy
Curebase eClinical software helps Krystal Biotech bring patient-friendly innovation to rare disease trials
The Challenge
Patient Burden
Patients face a high daily treatment burden. Traditional NK management is inconvenient, difficult to adhere to, and life-impacting.
Research Challenge
Running innovative gene therapy trials efficiently while keeping the patient experience central to the study design.
Traditional Treatment Reality
- 6 eye drops daily
- Complex adherence requirements
- Significant quality of life impact
The Curebase Solution
How Curebase supported EMERALD 1 with digital-first data capture and oversight:
ePRO
Enabled participants to report symptoms and outcomes directly from their own devices, reducing site visits and ensuring higher data quality.
eConsent
Delivered a clear, mobile-friendly, remote consenting process so patients could understand and agree to participate without unnecessary clinic trips.
Engagement Tools
Automated reminders, scheduling, and patient communications kept participants adherent, supported, and connected throughout the study.
"Helping bring trials like this to life — efficiently, remotely, and with real patient focus — is exactly why we built Curebase."
The Impact
Curebase's role in enabling Krystal's breakthrough achievement
EMERALD 1 is just the beginning of this innovation
Reducing treatment burden and supporting life-changing innovation
By partnering with Curebase, Krystal Biotech was able to focus on what matters most — bringing innovative treatments to patients who need them — while we handled the digital infrastructure that makes modern, patient-centric trials possible.
See how Curebase powers modern clinical trials that put patients first.
Ready to transform your clinical trials with digital-first solutions?
Explore the Curebase Platform